Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Short Interest Down 95.4% in April

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the target of a large decline in short interest in the month of April. As of April 30th, there was short interest totaling 3,057 shares, a decline of 95.4% from the April 15th total of 66,281 shares. Based on an average daily volume of 600,227 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.0% of the company’s shares are sold short.

Analysts Set New Price Targets

Separately, Zacks Research upgraded Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 5th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Daiichi Sankyo presently has a consensus rating of “Buy”.

Daiichi Sankyo Stock Down 0.4%

OTCMKTS DSNKY traded down $0.07 on Wednesday, reaching $17.22. The company had a trading volume of 154,852 shares, compared to its average volume of 443,974. The firm has a market capitalization of $32.62 billion, a PE ratio of 18.32, a P/E/G ratio of 0.88 and a beta of -0.25. Daiichi Sankyo has a 1 year low of $15.56 and a 1 year high of $28.21. The firm has a 50-day moving average of $17.79 and a 200-day moving average of $20.25. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.69 and a quick ratio of 1.85.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its quarterly earnings results on Monday, May 11th. The company reported $0.15 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). The company had revenue of $3.76 billion during the quarter, compared to analysts’ expectations of $3.74 billion. Daiichi Sankyo had a return on equity of 15.74% and a net margin of 12.32%.Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. On average, equities research analysts anticipate that Daiichi Sankyo will post 1.26 EPS for the current fiscal year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.